

**Supplementary Table 5:** Clinicopathologic characteristics of the exploratory subcohort in which we analysed differences in OS in the context of morphologic subtypes and therapy received. p-values were calculated by Fisher's exact tests except for \* where Chi-squared tests were used and † where unpaired, two-tailed t-tests.

	All subtypes			Multimodal therapy (MMT)			No MMT		
	MMT	No MMT	p-value	Solid/ trabecular	Tubulop./ microcystic	p-value	Solid/ trabecular	Tubulop./ microcystic	p-value
<b>Number of samples</b>	44	65		25	19		49	16	
<b>Mean age ± SE (years)</b>	62.1 ±1.66	68.0 ±1.31	<b>0.005†</b>	63.0 ±2.32	60.9 ±2.37	0.526†	69.5 ±1.38	63.6 ±3.07	<b>0.04</b>
<b>Gender</b>									
<b>male</b>	33	49	1.000	19	14	1.000	38	11	0.51
<b>female</b>	11	16		6	5		11	5	
<b>M/N score</b>									
<b>0</b>	26	17	<b>0.005 *</b>	14	12	0.294*	8	9	<b>0.01</b>
<b>1</b>	15	31		8	7		25	6	
<b>2</b>	3	12		3	0		11	1	
<b>Nuclear grade</b>									
<b>1</b>	24	32	0.301 *	11	13	0.143*	25	7	<b>0.03</b>
<b>2</b>	17	22		11	6		13	9	
<b>3</b>	3	11		3	0		11	0	
<b>Stage</b>									
<b>I/II</b>	14	27	0.663	8	6	0.304	21	6	1.00
<b>III/IV</b>	19	29		7	12		23	6	

\*MMT, multimodal therapy; tubulop., tubulopapillary; NA, not available; SE, standard error; M/N, mitosis/necrosis.